# US 2010/0168013 A1 · Neuromedin and FN-38 Peptides for Treating Psychiatric Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168013 A1
- Document ID: US20100168013A1
- Status: Published application
- Kind: A1
- Application number: 12/524,903
- Filed: 2008-02-04
- Published: 2010-07-01
- Earliest claimed: 2007-02-05
- Assignees: Amylin Pharmaceuticals, Inc.
- Inventors: Kevin D. Laugero; Michael R. Hanley; David G. Parkers; Paul Mcgonigle
- Web page: https://patentgrep.com/patent/US20100168013A1

## CPC

- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an NMX peptide, an FNX peptide, or an NMX receptor agonist, or analogs or derivatives thereof, to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for treating a psychotic disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a neuromedin peptide or an FN38 peptide to treat the psychotic disorder.

### Claim 17 (depends on 16)

The method of claim 16, wherein the psychotic disorder is schizophrenia.

### Claim 18 (depends on 16)

The method of claim 16, wherein the psychotic disorder is schizophrenia; schizophreniform disorder; schizoaffective disorder; delusional disorder; brief psychotic disorder; shared psychotic disorder; psychotic disorder due to a general medical condition; substance-induced psychotic disorder; or psychotic disorder not otherwise specified.

### Claim 19 (depends on 16)

The method of claim 16, wherein the psychotic disorder is schizoid personality disorder or schizotypal personality disorder.

### Claim 20 (depends on 16)

The method of claim 16, wherein the neuromedin peptide or the FN38 peptide has at least 80% sequence identity to the peptide comprising the amino acid sequence of
(SEQ ID NO: 5)
FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2.

### Claim 21 (depends on 16)

The method of claim 16, wherein the neuromedin peptide or the FN38 peptide has at least 90% sequence identity to the peptide comprising the amino acid sequence of
(SEQ ID NO: 5)
FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2.

### Claim 22 (depends on 16)

The method of claim 16, wherein the neuromedin peptide or the FN38 peptide comprises the amino acid sequence of
(SEQ ID NO: 5)
FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2.

### Claim 23 (depends on 16)

The method of claim 16, wherein the neuromedin peptide or the FN38 peptide comprises the amino acid sequence of:
(SEQ ID NO: 11)
YKVNEYQGPVAPSGGFFLFRPRN-NH2;
(SEQ ID NO: 13)
SDEEVQVPGGVISNGYFLFRPRN-NH2;
(SEQ ID NO: 14)
FLFHYSKTQKLGKSNSDEEVQVPGGVISNGYFLFRPRN-NH2;
(SEQ ID NO: 31)
FLFHYSKTQKLGKSNVVEEFQSPFASQSRGYFLFRPRN-NH2;
(SEQ ID NO: 51)
FLFHYSKTQKLGKSNEELQSPFASQSRGYFLFRPRN-NH2;
(SEQ ID NO: 52)
FLFHYSKTQKLGKSNVVEELQSPSRGYFLFRPRN-NH2;
(SEQ ID NO: 53)
FLFHYSKTQKLGKSNEELQSPSRGYFLFRPRN-NH2;
(SEQ ID NO: 54)
YSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2;
or
(SEQ ID NO: 64)
YSKTQKLGKSNEELQSPSRGYFLFRPRN-NH2.

### Claim 24 (depends on 16)

The method of claim 16, wherein the neuromedin peptide or the FN38 peptide comprises the amino acid sequence of SEQ ID NO:1, 2, 3, 4, 6, 7, 8, 9, 10, 12, 15, 16, or 17.

### Claim 25 (depends on 16)

The method of claim 16, wherein the neuromedin peptide or the FN38 peptide comprises the amino acid sequence of any one of SEQ ID NOs:32-50, 55-63, and 65-76.

### Claim 26 (depends on 16)

The method of claim 16, further comprising administering to the subject a therapeutically effective amount of a tricyclic antidepressant, a monoamine oxidase inhibitor, a selective serotonin reuptake inhibitor, a serotonin and noradrenaline reuptake inhibitor, or a second generation antipsychotic.

### Claim 27 (depends on 16)

The method of claim 16, further comprising administering to the subject a therapeutically effective amount of a second generation antipsychotic.

### Claim 28

A method for treating an anxiety disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a neuromedin peptide or an FN38 peptide to treat the anxiety disorder.

### Claim 29 (depends on 28)

The method of claim 28, wherein the anxiety disorder is a panic disorder, a specific phobia, a social phobia, an obsessive-compulsive disorder, a posttraumatic stress disorder, an acute stress disorder, or a generalized anxiety disorder.

### Claim 30 (depends on 28)

The method of claim 28, wherein the anxiety disorder is an anxiety disorder due to a medical condition, a substance-induced anxiety disorder, or an anxiety disorder not otherwise specified.

### Claim 31 (depends on 28)

The method of claim 28, wherein the neuromedin peptide or the FN38 peptide has at least 80% sequence identity to the peptide comprising the amino acid sequence of
(SEQ ID NO: 5)
FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2.

### Claim 32 (depends on 28)

The method of claim 28, wherein the neuromedin peptide or the FN38 peptide comprises the amino acid sequence of
(SEQ ID NO: 5)
FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2.

### Claim 33 (depends on 28)

The method of claim 28, wherein the neuromedin peptide or the FN38 peptide comprises the amino acid sequence of:
(SEQ ID NO: 11)
YKVNEYQGPVAPSGGFFLFRPRN-NH2;
(SEQ ID NO: 13)
SDEEVQVPGGVISNGYFLFRPRN-NH2;
(SEQ ID NO: 14)
FLFHYSKTQKLGKSNSDEEVQVPGGVISNGYFLFRPRN-NH2;
(SEQ ID NO: 31)
FLFHYSKTQKLGKSNVVEEFQSPFASQSRGYFLFRPRN-NH2;
(SEQ ID NO: 51)
FLFHYSKTQKLGKSNEELQSPFASQSRGYFLFRPRN-NH2;
(SEQ ID NO: 52)
FLFHYSKTQKLGKSNVVEELQSPSRGYFLFRPRN-NH2;
(SEQ ID NO: 53)
FLFHYSKTQKLGKSNEELQSPSRGYFLFRPRN-NH2;
(SEQ ID NO: 54)
YSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2;
or
(SEQ ID NO: 64)
YSKTQKLGKSNEELQSPSRGYFLFRPRN-NH2.

### Claim 34 (depends on 28)

The method of claim 28, wherein the neuromedin peptide or the FN38 peptide comprises the amino acid sequence of any one of SEQ ID NOs:1-4, 6-10, 12, 15-17, 32-50, 55-63, and 65-76.

### Claim 35

A method for treating schizophrenia in a human in need thereof comprising administering to the human a therapeutically effective amount of a peptide comprising the amino acid sequence of FLFHYSKTQKLGKSNVVEELQSPFASQSRGYFLFRPRN-NH2 (SEQ ID NO:5) to treat the schizophrenia.
